Thirdly, PROTAC is a novel technology that could specifically target any protein of interest, such as cancer cell surface markers (such as EGFR, ERBB2, and PD-L1), and induce its ubiquitination proteasome degradation [215,216,217,218]. This evidence concerns the gene CD274 and cancer.